Compare TG Therapeutics Inc (TGTX) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Western Union Co — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Western Union Co trades at $7.13 (market cap $2.20B). The key difference: TG Therapeutics Inc is far larger — about 3.5× Western Union Co's market cap, and Western Union Co pays a 13.33% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WU | |
|---|---|---|
Market Cap | $7.64B | $2.20B |
Sector | Health | Technology |
52-Week High | $59.06 | $10.28 |
52-Week Low | $26.94 | $6.36 |
Enterprise Value | $7.84B | $2.10B |
Dividend Yield | — | 13.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Western Union (WU) trades at $7.13, up 1.42% with bearish technical signals and mixed fundamentals. The stock shows attractive valuation metrics with P/E of 5.69 and P/S of 0.56, but faces revenue decline from $4.5B in 2022 to $4.05B in 2025. Recent Q2 2026 earnings missed estimates at $0.31 vs. $0.42 expected, continuing a trend of earnings underperformance despite strong profitability margins.
The outlook remains challenging with declining revenue trends and bearish analyst sentiment (57% Hold, 31% Sell). Key risks include competitive pressure in money transfer services and digital transition challenges. The consensus price target of $7.14 offers minimal upside potential from current levels, suggesting limited near-term growth prospects for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
